DOLUTEGRAVIR; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE
Pre-Launchdolutegravir; lamivudine; tenofovir disoproxil fumarate
NDAORALTABLET
Lifecycle
Pre-Launch
Data completeness
2/8 — Basic
DOLUTEGRAVIR; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE (dolutegravir; lamivudine; tenofovir disoproxil fumarate) by Shanghai Sunway Biotech is fixed-dose combination of the hiv‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see microbiology ()]. Approved for hiv-1 infection in adults, weighing at least 6 kg.
Drug data last refreshed 23h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
This is a fixed-dose combination antiretroviral tablet containing dolutegravir, lamivudine, and tenofovir disoproxil fumarate for the treatment of HIV-1 infection. The combination works through three complementary mechanisms: dolutegravir inhibits integrase, while lamivudine and tenofovir are nucleoside reverse transcriptase inhibitors. It is indicated for HIV-1 infected adults and pediatric patients weighing at least 6 kg.
Pre-Launch
Early-stage launch preparation with limited current market data; commercial teams are building go-to-market infrastructure and sales organization.
Mechanism of Action
fixed-dose combination of the HIV‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see Microbiology ()].
Indications (2)
Worked on DOLUTEGRAVIR; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE at Shanghai Sunway Biotech? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.